What the Zolgensma tumour reports mean for Novartis and AAV gene therapy safety
FDA is investigating Zolgensma malignancy risk after vector DNA integration was found in two tumours. Novartis has received nine reports.
Pharma & Biotech
Pharma & Biotech
Why Novartis Pharma AG’s Itvisma could redefine treatment pathways for older SMA patients
Novartis Pharma AG’s Itvisma gains CHMP support in SMA. Find out how gene therapy could reshape treatment for older patients in Europe.